Neuralstem, Inc. is focused on developing and commercializing of treatments for central nervous system disease based on transplanting human neural stem cells and small molecule drugs. The Company has developed and maintain a portfolio of patents and patent applications that form the base of its research and development efforts in the areas of neural stem cell research, small molecule research, and related technologies.
04/10/11Neuralstem shares jump over 13% on new stem cell patent
16/12/10Neuralstem Receives FDA Approval to Start Phase Ia Trial for Depression Drug
14/09/10Study Shows Neuralstem’s Stem Cells May Have Application To Treating Stroke
Recent Sector News
U.S. stocks rallied Thursday after some better-than-expected quarterly results from the likes of Caterpillar and 3M and strong manufacturing data from abroad. The gains follow a triple digit loss for the Dow yesterday, following a deadly attack in Canada.
Canadian biopharmaceuticals firm Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) jumped in early deals Wednesday after the company said it has begun limited manufacturing of a new therapeutic targeting the Ebola-Guinea virus, which is the viral variant responsible for the current epidemic in West Africa.
Tekmira's (NASDAQ:TKMR) (TSE:TKM) shares have been rising this week ever since the first US case of Ebola emerged in Texas, and are up another 8 percent today after announcing a $1.5 million milestone payment from agricultural giant Monsanto (NYSE:MON).
OrganiGram (CVE:OGI) is currently one of 13 licensed producers for medical marijuana so far in Canada under the government’s new regulations, but the company is the only provider east of Ontario and one of two producers (the sole publicly listed one) growing an organic product.
Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) extended gains on Tuesday after the company said it has taken another step to help combat the Ebola crisis by collaborating with an international consortium to provide an RNAi-based investigational drug for expedited clinical studies in West Africa.
Shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) (TSE:TKM) were jumping Monday afternoon after the FDA authorized the company to provide its TKM-Ebola treatment to people with confirmed or suspected Ebola infections.
Investors interested in Neuralstem recently viewed
- Silence Therapeutics (AIM: SLN) A leader in RNAi therapeutics
- e-Therapeutics plc (AIM: ETX) Systems Biology Drug Discovery
- Amphion Innovations (LON: AMP) Amphion builds shareholder value in the medical and technology sectors
- Sphere Medical (AIM: SPHR) Raising the Standard of Critical Care
- ImmuPharma PLC (AIM: IMM) Drug Discovery & Development to Treat Lupus, Cancer & MRSA